Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug;14(5):661-675.
doi: 10.1007/s11739-019-02035-1. Epub 2019 Jan 25.

Update on the treatment of Behçet's syndrome

Sinem Nihal Esatoglu  1 , Gulen Hatemi  2
Affiliations
Review

Update on the treatment of Behçet's syndrome

Sinem Nihal Esatoglu et al. Intern Emerg Med. 2019 Aug.

Abstract

Behçet's syndrome (BS) is a complex disease that shows important heterogeneity in clinical findings and physiopathology. Its treatment can be problematic as BS manifestations in different organs may respond differently to the same drug. The cornerstone of therapy for inducing remission is corticosteroids whereas immunomodulatory and immunosuppressive agents such as colchicine, azathioprine, cyclosporine-A, interferon-alpha, and cyclophosphamide are used as steroid-sparing agents and to prevent further relapses. However, a considerable number of patients continue to have mucocutaneous lesions despite therapy, and some patients require more aggressive treatment for refractory major organ involvement. Tumor necrosis factor alpha inhibitors, especially infliximab and adalimumab, are increasingly used for various refractory BS manifestations despite the lack of controlled studies. In this review, we aim to focus on both the traditional and new treatment modalities for BS, with more emphasis on recent data on newer agents.

Keywords: Behçet’s syndrome; Biologic agents; Management; TNF inhibitors; Treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Arch Dermatol. 2002 Apr;138(4):467-71 - PubMed
    1. Arthritis Rheumatol. 2014 May;66(5):1306-14 - PubMed
    1. Arthritis Rheumatol. 2018 Sep;70(9):1500-1507 - PubMed
    1. Dermatology. 2000;201(1):40-3 - PubMed
    1. Ann Intern Med. 1998 Mar 15;128(6):443-50 - PubMed

MeSH terms

LinkOut - more resources